Literature DB >> 29029150

Antibiotic Use and New-Onset Inflammatory Bowel Disease in Olmsted County, Minnesota: A Population-Based Case-Control Study.

Satimai Aniwan1,2, William J Tremaine1, Laura E Raffals1, Sunanda V Kane1, Edward V Loftus1.   

Abstract

BACKGROUND AND AIMS: Several studies have suggested significant associations between environmental factors and the risk of developing inflammatory bowel disease [IBD]. However, data supporting the role of antibiotics are conflicting. The aim of this study was to evaluate the association between antibiotic use and new-onset IBD.
METHODS: We conducted a population-based case-control study using the Rochester Epidemiology Project of Olmsted County, Minnesota. We identified 736 county residents diagnosed with IBD between 1980 and 2010 who were matched to 1472 controls, based on age, sex and date of IBD diagnosis. Data on antibiotic use between 3 months and 5 years before IBD diagnosis were collected. Logistic regression models were used to estimate associations between antibiotic use and IBD, and were expressed as adjusted odds ratio [AOR] with 95% confidence interval [CI].
RESULTS: Antibiotic use occurred in 455 IBD cases [61.8%] and 495 controls [33.6%] [p < 0.001]. In multivariate analysis, there were statistically significant associations between antibiotic use and new-onset IBD [AOR, 2.93; 95% CI, 2.40-3.58], Crohn's disease [CD] [AOR, 3.01; 2.27-4.00] and ulcerative colitis [UC] [AOR, 2.94; 95% CI, 2.23-3.88]. A cumulative duration of antibiotic use ≥ 30 days had the strongest AOR [6.01; 95% CI, 4.34-8.45]. AOR for those receiving antibiotics under the age of 18 years was 4.27 [95% CI, 2.39-7.91], 2.97 for age 18-60 years [2.36-3.75] and 2.72 for age > 60 years [1.60-4.67].
CONCLUSIONS: This population-based case-control study suggests a strong association between antibiotic use and the risk of both new-onset CD and new-onset UC. The risk was increased among all age-onset IBD.
Copyright © 2017 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com

Entities:  

Keywords:  Antibiotics; epidemiology; inflammatory bowel disease

Mesh:

Substances:

Year:  2018        PMID: 29029150      PMCID: PMC5881749          DOI: 10.1093/ecco-jcc/jjx135

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  36 in total

1.  Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe--an ECCO-EpiCom study.

Authors:  J Burisch; N Pedersen; S Cukovic-Cavka; N Turk; I Kaimakliotis; D Duricova; M Bortlik; O Shonová; I Vind; S Avnstrøm; N Thorsgaard; S Krabbe; V Andersen; J F Dahlerup; J Kjeldsen; R Salupere; J Olsen; K R Nielsen; P Manninen; P Collin; K H Katsanos; E V Tsianos; K Ladefoged; L Lakatos; G Ragnarsson; E Björnsson; Y Bailey; C O'Morain; D Schwartz; S Odes; M Giannotta; G Girardin; G Kiudelis; L Kupcinskas; S Turcan; L Barros; F Magro; D Lazar; A Goldis; I Nikulina; E Belousova; D Martinez-Ares; V Hernandez; S Almer; Y Zhulina; J Halfvarson; N Arebi; H H Tsai; S Sebastian; P L Lakatos; E Langholz; P Munkholm
Journal:  J Crohns Colitis       Date:  2013-12-07       Impact factor: 9.071

2.  Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival.

Authors:  E V Loftus; M D Silverstein; W J Sandborn; W J Tremaine; W S Harmsen; A R Zinsmeister
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

3.  Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease.

Authors:  Floris Imhann; Arnau Vich Vila; Marc Jan Bonder; Jingyuan Fu; Dirk Gevers; Marijn C Visschedijk; Lieke M Spekhorst; Rudi Alberts; Lude Franke; Hendrik M van Dullemen; Rinze W F Ter Steege; Curtis Huttenhower; Gerard Dijkstra; Ramnik J Xavier; Eleonora A M Festen; Cisca Wijmenga; Alexandra Zhernakova; Rinse K Weersma
Journal:  Gut       Date:  2016-10-08       Impact factor: 23.059

4.  Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca
Journal:  Am J Epidemiol       Date:  2011-03-23       Impact factor: 4.897

5.  Developmental dynamics of the preterm infant gut microbiota and antibiotic resistome.

Authors:  Molly K Gibson; Bin Wang; Sara Ahmadi; Carey-Ann D Burnham; Phillip I Tarr; Barbara B Warner; Gautam Dantas
Journal:  Nat Microbiol       Date:  2016-03-07       Impact factor: 17.745

6.  Population-based cases control study of inflammatory bowel disease risk factors.

Authors:  Richard B Gearry; Ann K Richardson; Christopher M Frampton; Andrew J Dodgshun; Murray L Barclay
Journal:  J Gastroenterol Hepatol       Date:  2010-01-14       Impact factor: 4.029

Review 7.  Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis.

Authors:  Ryan Ungaro; Charles N Bernstein; Richard Gearry; Anders Hviid; Kaija-Leena Kolho; Matthew P Kronman; Souradet Shaw; Herbert Van Kruiningen; Jean-Frédéric Colombel; Ashish Atreja
Journal:  Am J Gastroenterol       Date:  2014-09-16       Impact factor: 10.864

8.  Gut microbiota disturbance during antibiotic therapy: a multi-omic approach.

Authors:  Ana Elena Pérez-Cobas; María José Gosalbes; Anette Friedrichs; Henrik Knecht; Alejandro Artacho; Kathleen Eismann; Wolfgang Otto; David Rojo; Rafael Bargiela; Martin von Bergen; Sven C Neulinger; Carolin Däumer; Femke-Anouska Heinsen; Amparo Latorre; Coral Barbas; Jana Seifert; Vitor Martins dos Santos; Stephan J Ott; Manuel Ferrer; Andrés Moya
Journal:  Gut       Date:  2012-12-12       Impact factor: 23.059

9.  Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease.

Authors:  Kelly A Shaw; Madeline Bertha; Tatyana Hofmekler; Pankaj Chopra; Tommi Vatanen; Abhiram Srivatsa; Jarod Prince; Archana Kumar; Cary Sauer; Michael E Zwick; Glen A Satten; Aleksandar D Kostic; Jennifer G Mulle; Ramnik J Xavier; Subra Kugathasan
Journal:  Genome Med       Date:  2016-07-13       Impact factor: 11.117

Review 10.  Dietary fiber and prebiotics and the gastrointestinal microbiota.

Authors:  Hannah D Holscher
Journal:  Gut Microbes       Date:  2017-02-06
View more
  11 in total

1.  Impact of Obesity on the Management of Inflammatory Bowel Disease.

Authors:  Amanda M Johnson; Edward V Loftus
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-07

Review 2.  Helicobacter pylori Infection: New Facts in Clinical Management.

Authors:  Peter Malfertheiner; Marino Venerito; Christian Schulz
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

Review 3.  Where Do We Stand in the Behavioral Pathogenesis of Inflammatory Bowel Disease? The Western Dietary Pattern and Microbiota-A Narrative Review.

Authors:  Iwona Krela-Kaźmierczak; Oliwia Zakerska-Banaszak; Marzena Skrzypczak-Zielińska; Liliana Łykowska-Szuber; Aleksandra Szymczak-Tomczak; Agnieszka Zawada; Anna Maria Rychter; Alicja Ewa Ratajczak; Kinga Skoracka; Dorota Skrzypczak; Emilia Marcinkowska; Ryszard Słomski; Agnieszka Dobrowolska
Journal:  Nutrients       Date:  2022-06-17       Impact factor: 6.706

Review 4.  Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products.

Authors:  Karma Yeshi; Roland Ruscher; Luke Hunter; Norelle L Daly; Alex Loukas; Phurpa Wangchuk
Journal:  J Clin Med       Date:  2020-04-28       Impact factor: 4.241

5.  The long-term consequences of antibiotic therapy: Role of colonic short-chain fatty acids (SCFA) system and intestinal barrier integrity.

Authors:  Yuliia Holota; Taisa Dovbynchuk; Izumi Kaji; Igor Vareniuk; Natalia Dzyubenko; Tetiana Chervinska; Liudmyla Zakordonets; Viktoria Stetska; Liudmyla Ostapchenko; Tetiana Serhiychuk; Ganna Tolstanova
Journal:  PLoS One       Date:  2019-08-22       Impact factor: 3.240

6.  Prevalence and Impact of Obesity on Disease-specific Outcomes in a Population-based Cohort of Patients with Ulcerative Colitis.

Authors:  Amanda M Johnson; W Scott Harmsen; Satimai Aniwan; William J Tremaine; Barham K Abu Dayyeh; Edward V Loftus
Journal:  J Crohns Colitis       Date:  2021-11-08       Impact factor: 10.020

7.  Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden.

Authors:  Long H Nguyen; Anne K Örtqvist; Yin Cao; Tracey G Simon; Bjorn Roelstraete; Mingyang Song; Amit D Joshi; Kyle Staller; Andrew T Chan; Hamed Khalili; Ola Olén; Jonas F Ludvigsson
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-08-17

8.  Short and long-term effects of a synbiotic on clinical signs, the fecal microbiome, and metabolomic profiles in healthy research cats receiving clindamycin: a randomized, controlled trial.

Authors:  Jacqueline C Whittemore; Jennifer E Stokes; Nicole L Laia; Joshua M Price; Jan S Suchodolski
Journal:  PeerJ       Date:  2018-07-17       Impact factor: 2.984

9.  Effects of a synbiotic on the fecal microbiome and metabolomic profiles of healthy research cats administered clindamycin: a randomized, controlled trial.

Authors:  Jacqueline C Whittemore; Jennifer E Stokes; Joshua M Price; Jan S Suchodolski
Journal:  Gut Microbes       Date:  2019-02-01

Review 10.  Exploitation of Marine-Derived Robust Biological Molecules to Manage Inflammatory Bowel Disease.

Authors:  Muhammad Bilal; Leonardo Vieira Nunes; Marco Thúlio Saviatto Duarte; Luiz Fernando Romanholo Ferreira; Renato Nery Soriano; Hafiz M N Iqbal
Journal:  Mar Drugs       Date:  2021-03-30       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.